A promising pancreatic cancer vaccine trial in New Jersey. Phase I.

To determine the tolerability of delivering two standard doses of intratumoral recombinant fowlpox PANVAC vaccine (PANVAC-F; falimarev) when administered in combination with subcutaneous recombinant vaccinia PANVAC vaccine (PANVAC-V; inalimarev) followed by subcutaneous PANVAC-F vaccine and sargramostim (GM-CSF) in patients with unresectable locally advanced or metastatic pancreatic cancer.